NTRK fusions discovered involved TRKA (NTRK1) in 4 patients (67%), and TRKC (NTRK3) in 2 patients (33%) with 5 unique fusion partners in primary (3/6, 50%) or metastatic tumor tissue (3/6, 50%). This evidence concerns the gene NTRK3 and metastatic neoplasm.